INTRODUCTION
Bone remodeling and regeneration are ongoing processes occurring throughout adult life. Bone-marrow-derived skeletal stem cells (BMSCs; also known as stromal or mesenchymal stem cells) are adult multipotent stem cells that can differentiate into several mesodermal lineages including osteoblasts, adipocytes, and chondrocytes. In addition to bone marrow, mesenchymal stem/stromal cell (MSC)-like cells can be obtained from other sources including dental tissue and adipose tissue. Because MSCs can be easily obtained and expanded in ex vivo cultures, they are an attractive source for regenerative medicine applications including bone tissue regeneration.
Differentiation of BMSCs toward osteoblasts includes cell proliferation, lineage commitment, and differentiation into the mature phenotype. 1 This complex sequence of events is regulated by an intricate network of signaling pathways, among others bone morphogenetic proteins (BMPs) and WNT signaling. 2, 3 The complexity of the signaling pathways and the factors therein are regulated at many levels including post-transcriptional and post-translational regulation. Despite extensive studies, the gene-regulatory network of the osteoblastogenesis landscape is still under investigation.
MicroRNAs (miRNAs) are small, non-coding RNAs of about 22 nt encoded by the genome, and they serve as post-transcriptional regulators by suppressing the expression of their target mRNAs. miRNAs are usually transcribed by polymerase II and cleaved by the RNase III enzyme, Drosha, into pre-miRNAs and exported to the cytoplasm. Here, they are further processed by another RNase III enzyme, Dicer, into miRNAs duplexes. One arm in the duplex is selectively incorporated into the RNA-induced silencing complex (RISC), where it guides the RISC complex to its mRNA target by base-pair complementarity to the 3 0 UTR of the target mRNA. Full complementarity is rare and leads to mRNA cleavage, whereas the more common scenario of partial complementarity destabilizes the RNA by recruiting RNA exonucleases and/or repressing translation. 4 Extensive studies have demonstrated that miRNAs are ubiquitous and potent regulators of numerous processes including development, metabolism, tumorigenesis, cell survival and proliferation. Many miRNAs have been reported to exert a significant impact on osteoblastogenesis and bone formation by regulating the post-transcriptional turnover of mRNAs involved in the bone-related pathways. For example, miR-138 regulates the focal adhesion kinase (FAK) signaling pathway, which activates Runx2 and Osterix; 5 miR-34a
regulates JAG1, a Notch 1 ligand; 6 and miR-335 regulates DKK1 in the Wnt signaling pathway to promote osteogenesis. 7 Several studies have reported the differential expression of miRNAs during osteoblastogenesis; however, most of these studies focused on a few miRNA candidates. [8] [9] [10] The landscape depicting miRNA expression over the whole course of osteoblastogenesis from undifferentiated stem cells to mature osteoblasts with higher temporal resolution is needed for a better understanding of miRNAs' role in different phases of osteoblastogenesis. Thus, we performed deep sequencing of miRNAs in human BMSCs (hBMSCs) undergoing osteoblast differentiation, examined the temporal expression of miRNAs during the proliferation, cell matrix maturation, and mineralization stages of osteoblastogenesis, and identified several miRNAs with enhancing effects on osteoblastogenesis and in vivo ectopic bone formation. We also demonstrate that scaffolds functionalized with miRNA anti-miRs can promote bone regeneration in vitro and in vivo.
RESULTS

Differential Expression of miRNAs during Osteogenesis
hBMSC-telomerase reverse transcriptase (TERT) cells were differentiated into osteoblastic cells, and differentiation was confirmed by qRT-PCR, alkaline phosphatase (ALP) activity, ALP staining, and alizarin red S (ARS) staining, which are hallmarks of osteoblastogenesis ( Figure S1 ). Cells were harvested at eight time points (0 hr, 6 hr, 12 hr, 24 hr, day 3, day 7, day 10, and day 13), and small RNAs in the range of 18-30 nt were sequenced on the HiSeq 2000 sequencer using 50-bp single-end sequencing.
To investigate the global changes in miRNA expressions, we performed a principal component analysis (PCA). All biological triplicates clustered together, demonstrating high reproducibility of the data ( Figure S2A ). The expression of each miRNA at each time point (in triplicates) is shown on the heatmap in Figure 1A . Most miRNAs were downregulated, with a significant decline in expression occurring between days 1 and 3. In general, very few miRNA changed expression levels in the initial 6 hr. At 12 hr the expression level of many miRNAs started to decrease and was further downregulated throughout osteoblastogenesis until day 13. A small, distinct group of miRNAs was upregulated at later stages of osteoblastogenesis (days 7-13).
We classified miRNAs according to their abundance by averaging expression levels across the eight time points. miR-21, miR-143, and miR-22 were very highly expressed (>100,000 reads per million [RPM]), 13 were highly expressed (10,000-100,000 RPM), 137 miRNAs were expressed at intermediate levels (100-10,000 RPM), whereas 223 miRNAs exhibited low expression levels (10-100 RPM) ( Figure S2B ). To decrease the risk of false positives, we chose a stringent cutoff of miRNAs with expression levels >100 RPM for at least one time point, which resulted in a total of 204 miRNAs.
Temporal Functions of miRNA Clusters
We employed weighted gene co-expression network analysis (WGCNA) to identify miRNAs displaying similar expression patterns defined by Pearson correlation >0.8. miRNAs were grouped into 15 groups (indicated by a color in Figure S2C ) showing distinct expression profiles ( Figures S3 and S4 ). The 15 groups were further grouped into four main classes showing similar overall expression kinetics ( Figures 1B and S2C) . Previous RNA profiling studies indicate that in vitro osteoblastogenesis can be separated into three distinct phases: proliferation, matrix maturation, and mineralization ( Figure 1C) . 11 In our analysis, we sought to observe the changes occurring during the transitional stages: between proliferation and matrix maturation, and between matrix maturation and mineralization. Previous studies have also shown that cell-cycle arrest marks the initiation of differentiation. 12, 13 To better resolve expression changes, we divided in vitro osteoblastogenesis into the following phases: early proliferation (days 0-1), cell-cycle arrest (days 1-3), matrix maturation (days 3-7), and early (days 7-10) and late mineralization (days 10-13) ( Figure 1C ). Class 1, which exhibited an overall downregulation upon osteoblastogenesis, includes the red, blue, brown, turquoise, green, and yellow groups. Therein, the two largest groups are the blue and turquoise groups, which account for 45 and 52 miRNAs, respectively. All six groups were highly downregulated at the onset of osteoblastogenesis, particularly between days 1 and 3, coinciding with changes from cell proliferation to cell-cycle arrest. Only two groups in class 1 (turquoise and green) regained expression at days 7 and 10, respectively, during mineralization. Class 2 includes the black and green-yellow groups that are distinctly upregulated at early time points with peaks at days 1 and 3 coinciding with early proliferation and cell-cycle arrest, respectively. Class 3 includes the magenta, pink, and purple groups, which are all upregulated during late mineralization (days 10-13). Finally, class 4, including tan, salmon, cyan, and midnight-blue groups, were upregulated from day 7 corresponding to the early matrix maturation phase of osteoblastogenesis.
Functional Studies of Selected miRNAs
The expressions of a few miRNAs from miRNA sequencing (miRNAseq) were validated by qRT-PCR ( Figure S5 ). To investigate the effect of miRNAs, we selected 31 miRNAs (Table S3 in Data S1) based on having the highest fold changes within the first 3 days following osteoinduction, and their effects on osteoblastogenesis were investigated. Among these, 13 miRNAs were previously reported to regulate osteoblastogenesis; however, some miRNAs exhibited a different ALP activity is a marker for osteoblastogenesis, and this was used to assess the cells following transfection with miRNA mimics or antimiRs ( Figure 2 ). Overexpression and inhibition of miRNAs were confirmed ( Figure S6 ). Both mimics and anti-miRs were introduced to prevent misinterpretation of off-target effects. Follow-up studies were performed on miRNAs with mimics and anti-miRs that exhibited opposing effects on ALP activity. We found that 24 miRNAs fulfilled this criterion, and 19 of them inhibited ALP activity when overexpressed. This is consistent with the miRNA-seq results where most miRNAs were downregulated in the first 3 days of osteoblastogenesis. There were two exceptions to this: let-7d (black group) and miR-34c (midnight blue) ( Figures S3 and S4 ). Consistent with a positive role in osteoblast differentiation, let-7d enhanced ALP activity when overexpressed and was also upregulated during the first 3 days. Overexpression of miR-34c inhibited ALP activity while being only upregulated toward the later stages (from day 7) of osteoblastogenesis. The highest ALP activity was obtained with anti-miRs of miR-222, miR-210, miR-138, miR-423, and miR-146b, and the strongest reduction of ALP activity was observed using mimics of miR-138, miR-146a, miR-146b, miR-222, and miR-512. Only the mimics of let7d and miR-193a enhanced ALP activity with the opposing effect by their respective anti-miRs.
ALP staining was performed to substantiate the results ( Figure S7A ). Based on the ALP staining, let-7b, miR-192, and miR17 did not enhance ALP staining and were excluded from further screens. One of the hallmarks of in vitro osteoblastogenesis is the ability to form mineralized matrix upon osteoinduction; this is visualized by ARS staining (Figures S7B and S7C). ARS staining revealed that miRNAs regulated in vitro matrix mineralization to varying extents. Overall, miR-512, miR-146a and miR-146b, miR-320a, miR-210, miR-222, miR-423, and miR-138 consistently acted as negative regulators of osteoblastogenesis across all three assays: ALP activity, ALP staining, and ARS staining (Figures 2 and S7 ). The strongest phenotype was observed for miR-320a, miR-210, miR-222, miR-423, and miR-138; these were selected for further screening.
We next examined for the ability of the selected miRNAs to regulate gene expression of osteoblastic markers ( Figure 3A ). Overexpression of all five miRNAs inhibited the expression of ALP mRNA, while the anti-miRs enhanced the expression. For RUNX2, the master transcriptional regulator of osteoblast phenotype, all the mimics inhibited RUNX2, and only anti-miR-320a and anti-miR-423 significantly upregulated RUNX2 mRNA expression ( Figure 3B ).
To confirm these results in primary hBMSCs, we transfected primary hBMSCs with the anti-miRs of miR-320a, miR-210, miR-222, miR-423, and miR-138. Following osteoblast induction, ALP activity and ARS staining of mineralized matrix were assessed ( Figures 3C and 3D ). The ALP activity and ARS staining increased when these miRNAs were inhibited, consistent with the effect seen in hBMSC-TERT cells. We corroborated these results by hydroxyapatite (HA) staining in the presence of low b-glycerophosphate concentration in induction medium 14 ( Figure S8 ). We obtained reproducible results with four mimics and anti-miRs (miR-138, miR-210, miR-222, and miR-423). Interestingly, both miR-320a mimic and anti-miR resulted in increased HA staining. The morphology of the stained HA also resembled lacunae and canaliculi-like structures of ossified bone, suggesting the presence of HA. This phenotype was particularly pronounced for anti-miR-222-and anti-miR-423-treated cells, demonstrating that these two miRNAs are important regulators of mineralization in osteoblastogenesis.
Since we discovered a panel of miRNAs that regulate in vitro osteoblastogenesis, we studied their synergistic effects using ARS staining to quantify the mineralized matrix as a readout. Anti-miRs with the most significant effects (miR-138, miR-210, miR-222, miR-423, miR-500a, miR-512, miR-518b, and miR-941) were chosen, and cells were cotransfected with combinations of two anti-miRs followed by in vitro osteoinduction ( Figure 4 ). The most potent single regulators were miR-138, miR-222, and miR-423, consistent with the above results. The strongest additive effect was seen in cells cotransfected with the anti-miRs of miR-138 with miR-222 or miR-423 when compared with transfecting with antimiRs of miR-138, miR-222, or miR-423 alone. These results show that miRNAs can act synergistically to enhance in vitro osteoblastogenesis.
Scaffold-Mediated Delivery of Anti-miR-222 and Anti-miR-423 Enhances In Vitro Osteoblastogenesis
Scaffolds in bone tissue engineering are typically used to provide mechanical support while the damaged bone is being repaired. Because they are situated at the immediate site of repair, they can function as an excellent vehicle to deliver biomolecules that promote tissue repair. To address this, we tested whether anti-miR-222 and anti-miR-423 promoted osteoblast differentiation when reverse transfected into hBMSCs via a scaffold.
Reverse transfection was validated using the hBMSC-TERT-GFP cell line. 15 Polycaprolactone (PCL) scaffolds were functionalized with transfection mixes and stored for 3 days or 2 weeks, following which the cells were seeded onto the scaffolds. GFP was successfully knocked down in cells reverse transfected with short interfering RNA against GFP (siGFP) ( Figure S9 ), and there was no significant difference in knockdown efficiency when the scaffolds were stored for 3 days or 2 weeks, suggesting that functionalized scaffolds can be stored for a significant amount of time without losing its RNAi functional capabilities. Anti-miR-222 and anti-miR-423 were then tested using the same approach. hBMSC-TERT cells growing on anti-miR-222-and anti-miR-423-coated scaffolds had significantly higher ALP activities compared with controls ( Figure 5A ). The matrix calcium deposition was assessed visually using HA and ARS staining of scaffold sections. In both cases, the cells seeded onto anti-miR-222 and anti-miR-423 functionalized scaffolds produced more calcium and HA than the control ( Figures 5C and 5D ). Next, the calcium deposits were quantified; cells grown on anti-miR-222 and anti-miR-423 both yielded higher mineralized matrix than the control as reflected by the calcium content per scaffold ( Figure 5B ). These results show that anti-miR-222 and anti-miR-423 can be delivered to stem cells when situated in a scaffold and improve osteogenesis.
Inhibition of miR-222 Enhances Ectopic Bone Formation In Vivo
Because anti-miR-222 and anti-miR-423 enhanced osteoblastogenesis in vitro, we examined whether bone formation is enhanced in vivo.
hBMSC-TERT cells were first transfected with mimics or anti-miRs of control, miR-138, miR-222, or miR-miR-423. The pre-transfected cells were loaded onto HA/tricalcium phosphate (HA/TCP) scaffolds and implanted subcutaneously into non-obese diabetic/severe combined immunodeficiency (NOD/SCID). 16 After 8 weeks the scaffolds were harvested, and bone formation was quantified by assessing the Multiple-group comparisons using ANOVA were used to compare between the groups. Results are presented as mean ± SD from three independent experiments. *p < 0.05.
area of bone formed per total scaffold area. Figure 6 shows that bone formed in the presence of mimics for miR-138, miR-222, and miR-423 and was not significantly different from the control. However, anti-miR-222 and anti-miR-138 increased bone formation ( Figure 6 ). In contrast with the in vitro experiments, anti-miR-423 did not enhance in vivo bone formation.
Inhibition of miR-222 Upregulates CDKN1B
In our in vitro and in vivo osteoblastogenesis and bone formation screen, miR-222 generally outperformed the other miRNAs; thus, we searched for possible miR-222 targets. Using miRNA target prediction algorithms (TargetScan and miRDB), we identified cyclindependent kinase inhibitor 1B (CDKN1B) as one of the strongest target candidates. miR-222 belongs to the same family as miR-221, and they share high sequence homology. The 3 0 UTR of CDKN1B has two miR-222/miR-221 binding sites embedded in its 3 0 UTR, and the two seeds are highly conserved ( Figure 7A) . Consistent with previous studies, CDKN1B is induced upon differentiation ( Figure 7B ). hBMSC-TERT cells were transfected with mimics or anti-miRs of miR-222 and induced for 3 days followed by mRNA isolation, to investigate whether CDKN1B is regulated by miR-222 upon osteoblast differentiation. miR-222 mimics inhibited CDKN1B, whereas anti-miR-222 upregulated CDKN1B ( Figure 7C ). Finally, in order to determine whether CDKN1B is a direct target of miR-222, we performed luciferase assays. Two luciferase reporters were used: one contained the wild-type 3 0 UTR of CDKN1B (WT CDKN1B 3 0 UTR), whereas the other contained the 3 0 UTR with mutations in both binding sites (DM CDKN1B 3 0 UTR). The two vectors were cotransfected with either the mimic or anti-miR of miR-222 into cells, and their luciferase activities were assessed. miR-222 mimic downregulated the luciferase activity of WT CDKN1B 3 0 UTR, whereas anti-miR had the opposite effect (Figure 7D) . In contrast, the luciferase activity of DM CDKN1B 3 0 UTR was comparable or higher than WT CDKN1B 3 0 UTR cotransfected with mimics and anti-miRs. Taken together, this suggests that miR-222 targets CDKN1B.
DISCUSSION
Global miRNA expression in MSCs undergoing osteoblast differentiation has been reported in a number of studies, [8] [9] [10] and it is well established that cellular RNAs are differentially expressed through sequential stages of in vitro osteoblastogenesis: cell proliferation, matrix maturation, and mineralization. However, most of these studies included few time points during the differentiation period or examined only the mature osteoblastic phenotype. Our current study reports a detailed chronological analysis of global miRNA-seq of hBMSCs undergoing osteoblastogenesis. We observed that the most significant changes in miRNA expression occurred between days 1 and 3, which corresponds to the shift from proliferation to cell-cycle arrest as the cells prepare for differentiation. This is also evident in our previous RNA-seq results, where numerous cell-cycle proteins had a change in expression between days 1 and 3 ( Figure S10 ). Previous BMSC miRNA analyses made use of microarrays to determine miRNA expression. This is limited by the probes used, which can cause a bias in the detected transcripts. Thus, earlier studies do not provide a bona fide global analysis of miRNA expression during osteoblastogenesis. Overall, our results show that miRNAs are differentially expressed early on in differentiation, and most miRNAs are downregulated upon osteoinduction. Because earlier studies used miRNA microarrays, it is difficult to compare the global trend in miRNA expression. However, one study revealed an overall downregulation of miRNAs in KUSA-A1 cells (murine BMSC cell line) when differentiated to osteoblastic cells in vitro for 14 days, 10 which is consistent with our study. Contrastingly, a miRNA-seq analysis on osteoblastogenesis of periodontal ligament stem cells (PDLSCs) showed that 37 miRNAs were downregulated and 60 miRNAs were upregulated by day 14 of differentiation. 17 The differences could be attributed to a difference in cell origin and differentiation efficiency. 18, 19 It is also plausible that osteogenic induction of BMSCs results in osteoblasts, whereas osteogenic induction in PDLSCs results in odontoblasts. Our miRNA-seq and validation screen yielded 11 new miRNAs and 8 miRNAs that were reported in other studies (Table S3 in Data S1) that regulated osteoblastogenesis. miR-210 and miR-378a promoted osteogenesis in rodent cells, 20, 21 which contrasts the inhibitory effects observed in our study employing hBMSCs, whereas miR-34c and miR-146a inhibited osteoblastogenesis in rodent cells, 21, 22 which is in agreement with our study. The remaining four were studied in human MSCs; miR-222, miR-31 (also in rats), and miR-138 inhibited osteoblastogenesis, 5,9,23-25 which was consistent with our study, whereas miR-17 upregulated osteoblastogenesis, which is in contrast with our study. 26 These results show that some miRNAs are evolutionary conserved and play a similar role across species such as miR-31 and miR-34c, whereas other miRNAs, such as miR-210 and miR-378a, exhibit species specificity. The reason for the mixed phenotype of some miRNAs is unclear but may reflect differences in time points, cell source, donor age, species-specific effects, efficiency of differentiation, or a more complex regulation of indirect targets. 27 Interestingly, several circulating miRNA biomarkers in osteoporosis (including let-7d-5p, miR-31-5p, and miR-29b-3p) are identified as differentially expressed miRNAs in our study. [28] [29] [30] Because a multitude of tissues secrete circulating miRNAs, including muscles and adipose tissues, it would be interesting to further study the role of these miRNAs under both healthy and osteoporotic conditions.
The miRNAs that presented the strongest phenotypes in all our osteogenic assays were miR-138, miR-210, miR-222, and miR-423. miR-210 exhibited opposite effects when compared with previous studies as described above. miR-138 and miR-222 were consistent with previous studies: both miR-138 and miR-222 were downregulated after osteoinduction. 5, 24 Both are also reported to target key players in osteogenesis such as PTK2 by miR-138, and Smad5 and Runx2 by miR-222. Interestingly, both overexpression and the inhibition of miR-320a in primary hBMSCs resulted in an increase in HA staining, which was not observed in our ALP and ARS assays in hBMSC-TERT. Our hBMSC-TERT results were consistent with another study where miR-320a inhibited osteogenesis via HOXA10, while the anti-miR increased osteogenesis. 31 The miR-320 family is also conserved in adipogenesis. An inverse relationship in the signaling pathways is often observed between adipogenesis and osteogenesis. 32 Indeed, the miR-320 family is upregulated after adipoinduction, and overexpressing miR-320 increased adipogenesis, while inhibiting osteogenesis by targeting RUNX2. 33 This either indicates the possibility of an off-target effect in primary BMSCs or that miR-320a could regulate factors that could lead to excess apatite formation when both inhibited and overexpressed. Finally, miR-423 has yet to be studied extensively. To date, there are only two osteogenesis studies describing any effect of miR-423, both of which are related to culturing cells on biomaterials (Bio-Oss and PerioGlas). 34, 35 When cells were cultured on these materials, miR-423 was upregulated. This indicates a role for miR-423 in mechanotransduction in osteogenesis or a response to chemicals from the biomaterials.
3D scaffolds, functionalized with bone-promoting therapeutics, are an attractive strategy as a means to replace bone defects. Gene expression therapeutics including plasmid DNA, siRNA, and miRNAs/antimiRs have been delivered using viral and non-viral nucleic acids delivery methods. 36 The transient expression of miRNAs using non-viral delivery methods may be best suited to initiate the osteoblastic differentiation program of stem cells. Although the stability and delivery of RNA are still challenging in vivo, the small size and fully modified nature of anti-miRs make them suitable for in vivo applications. 37, 38 Anti-miR-423 and anti-miR-222 functionalized scaffolds increased osteogenic differentiation in 3D culture. To date, miRNAs have been incorporated onto scaffolds by surface functionalization methods such as post-seeding or soak-loading. 39, 40 The advantage of the lyophilization method in our study is the improved long storage time and the avoidance of organic solvents when depositing miRNA complexes.
The results from our screen, 3D culture, and in vivo studies show that miR-222 is a potent osteogenic regulator, and we identify CDKN1B mRNA as a putative direct target. miR-222/221 is well studied in regulating CDKN1B in various cancers. [41] [42] [43] Previous studies have also shown that CDKN1B regulate osteoblast differentiation through cell-cycle arrest, 13 and cell-cycle arrest is a prerequisite for differentiation. 12, 44 CDKN1B is expressed during both proliferation and osteoblast maturation, whereas CDKN1A is expressed only during proliferation. Intriguingly, Drissi et al. 13 have reported that knockout of CDKN1B expression in mice results in the formation of more progenitor cells and increased bone formation, which contrasts with our results that showed increased CDKN1B led to enhanced ectopic bone formation. It is plausible that in vivo compensatory mechanisms are responsible for the observed differences, for example, upregulation of the CDKN1A gene during osteoblast maturation, which was observed in CDKN1B-deficient mice. 13, 42 In accordance with this, recent studies have shown that inhibiting miR-222 enhanced osteogenesis in vitro and fracture healing in the femur of rats. 23, 24 Cell-cycle regulation is essential for hBMSC self-renewal and growth, and this occurs through the inhibition of cell-cycle inhibitors such as CDKN1B and CDKN1A. 45 Here, we show that CDKN1B is inhibited by miR-222. Upon osteoinduction, miR-222 is downregulated, allowing for CDKN1B to be expressed, and this negative correlation enables the switch from proliferation to cycle arrest and differentiation. Regulators that facilitate cell-cycle arrest to differentiation are attractive targets for osteoinduction to drive differentiation because it occurs in early differentiation. This provides the possibility that an early dose of anti-miR provided by the scaffold may facilitate the switch in program, after which BMSCs can differentiate and facilitate healing by paracrine and autocrine factors.
Identification of bone-formation-enhancing miRNAs is thus relevant for bone tissue engineering. The strategy of functionalization of implantable scaffolds with osteogenic factors such as anti-miR-222 is likely to be clinically usable in future treatments of severe bone fractures or trauma-induced bone defects.
MATERIALS AND METHODS
This work was done at iNANO, Aarhus University, Aarhus, Denmark. The animal experiments were performed at KMEB, Southern Denmark University, Odense, Denmark.
Cell Culture
We employed the well-characterized telomerized hBMSC-TERT cell line previously developed in our laboratory by overexpressing the human telomerase reverse transcriptase in hBMSCs; 46 the cells express all of the characteristics of primary hMSCs, including ectopic bone and bone marrow formation, are non-tumorigenic, and have a normal karyotype. We have previously demonstrated the relevance in this model using mRNA-seq. 47 Cells were cultured in growth medium (minimum essential medium [MEM] supplemented with 10% fetal bovine serum [FBS] and 1% P/S) at 5% CO 2 and 37 C. Primary hBMSCs were bought from ATCC and grown in DMEM low glucose supplemented with 10% FBS and 1% P/S.
Cell Transfection
miRNA mimics or anti-miRs were transfected into hBMSC-TERT or primary hBMSCs at a final concentration of 50 nM using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The miRNA mimics and anti-miRs used were from GenePharma (Shanghai, China). A full list of the sequences is given in Table S1 of Data S1. Figure S1 .
miRNA Library Construction and Sequencing
Total RNA was extracted with TRIzol (Invitrogen) following the manufacturer's protocol, treated with DNase I, and purified again with TRIzol. RNA integrity was analyzed with the Agilent RNA 6000 Nano chip on the Agilent 2100 Bioanalyzer (Agilent Technologies). The miRNA library was prepared with the TruSeq Small RNA Sample Prep Kit (Illumina) following the manufacturer's protocol. Library quality was assessed with the High Sensitivity DNA kit (Agilent). The miRNA library was sequenced at Beijing Genomics Institute (BGI) on the HiSeq 2000 (Illumina) as 50-bp single-end reads (GEO: GSE107279).
Deep Sequencing Analysis and Data Processing
Sequencing of the small RNA libraries yielded a total of 89 million reads, after which they were processed using the BION-ncRNA pipeline (N. Larsen and J.K., unpublished data) to filter and profile the miRNA expression data. Duplicated reads were eliminated and sequentially matched to the following datasets: (1) human miRNAs, (2) miRNAs from other organisms, (3) large subunit (LSU) rRNA (90% complementarity), (4) small subunit (SSU) rRNA (90% complementarity), and (5) , and other non-coding RNAs [ncRNAs]) (90% complementarity). The databases used were miRBase version 17, Silva rRNA database (https://www.arb-silva.de/), and fRNAdb (https://www.ncrna.org/frnadb/). The miRNAs were then normalized to RPM. For PCA, heatmap, and gene co-expression network analysis (WGCNA), miRNAs (n = 204) with a minimum expression of 100 RPM in one or more samples were extracted and log2 transformed. PCA was performed and visualized in R using princomp and ggplot2, respectively. Heatmaps were produced with the MultiExperiment Viewer. 48 The R package, WGCNA, was used to find miRNAs that cluster together based on Pearson correlation of their expression values (see Langfelder and Horvath 49 and tutorials described herein). WGCNA was run with the hard-thresholding adjacency function (signumAdjacencyFunction), set at a Pearson correlation threshold of 0.8.
Osteoblast Phenotype Evaluation
ALP activity was determined as previously described. 50 ARS staining for in vitro mineralized matrix formation was performed by first fixing the cells with 70% ethanol at À20 C for 1 hr. The cells were washed with PBS and stained with 40 mM ARS (pH 4.2) (Sigma) for 10 min at room temperature, after which the excess dye was washed off with double-distilled water (ddH 2 O) and PBS. The ARS stain was then eluted and quantified using acetic acid extraction as previously described. 51 HA was stained using the OsteoImage Bone Mineralization Assay (Lonza) following the manufacturer's protocol.
qRT-PCR Analysis
Total RNA was extracted with TRIzol reagent (Invitrogen), and cDNA was prepared with the qScript cDNA SuperMix kit (Quanta). qPCR was performed using the primers listed in Table S2 of Data S1 and detected with Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) on the LightCycler 480 Instrument II (Roche). miRNA expression was quantified with TaqMan microRNA assays (Applied Biosystems). miRNAs were reverse transcribed with qRT-PCR probes, and amplification was performed with TaqMan Universal PCR Master Mix II according to the manufacturer's instructions (Applied Biosystems) and detected on the LightCycler 480 Instrument II (Roche).
Dual-Luciferase Reporter Assays
The pGL3-CDKN1B-3 0 UTR and the pGL3-CDKN1B-3 0 UTR DM vectors were kind gifts from Dr. Reuven Agami. Luciferase assays were performed using the Dual-Luciferase Reporter Assay system (Promega). For the regulation of CDKN1B by miR-222, HEK293 cells were seeded at 70,000 cells/well and cotransfected with 100 ng of pGL3-CDKN1B-3 0 UTR or pGL3-CDKN1B-3 0 UTR DM and 10 ng pRL-TK, followed by transfection with 25 nM miR-222 mimics or anti-miRs, or control mimics or anti-miRs. Luciferase activity was measured the next day on the FLUOstar OPTIMA Microplate Reader (BMG LABTECH), and Firefly luciferase activity was normalized to Renilla luciferase activity. Each experiment was performed in triplicates.
Scaffold Fabrications
The PCL scaffolds were prepared as previously reported. 52 In brief, scaffolds were made from PCL (Sigma) with a molar mass of 70-80 kDa by fused deposition modeling with a BioScaffolder (Sys+Eng, Germany) and extruded with a 200-mm needle for 200-mm-thick fibers. Cylindrical scaffolds with 2 mm thickness and 5 mm in diameter were punched out of the printed PCL mat. The scaffolds were treated with 5 M NaOH for 3 hr to increase hydrophilicity, washed with ddH2O, disinfected with 70% ethanol, and dried.
Scaffold Functionalization and Reverse Transfection
To adhere anti-miRs to the scaffold, we mixed 3.75 mL of anti-miR-222 or anti-miR-423 (from stocks of 20 mM) with 3.75 mL of Lipofectamine 2000 and 250 mL of serum-free media for 30 min. The mixture was then added to the 3D-printed PCL scaffolds at 30 mL/scaffold, frozen at À80 C for 30 min, and lyophilized in the Free Zone Triad Freeze Dry System (Lapcono) at À20 C and 12 mT for 24 hr. The functionalized scaffolds were placed in a 24-well dish with hydrophobic surfaces to lower cellular attachment to the plates. hBMSC-TERT cells were then seeded onto the scaffolds by adding 200,000 cells in 30 mL of growth media and distributing it over the scaffold. The cell-seeded scaffolds were incubated for 2 hr, allowing the cells to attach to the scaffolds, after which 1 mL of media was added to each well for reverse transfection for 24 hr. Cells were then induced as above.
Cellular Phenotyping on PCL Scaffolds
The scaffolds were washed in PBS, transferred to an Eppendorf tube containing 300 mL of PBS, and frozen at À20 C overnight. The samples were then thawed and sonicated in intervals of 1 s on and 5 s off at an amplitude of 50%. One hundred microliters of this was taken out for ALP activity measurement by mixing with 50 mL of the ALP substrate (1 mg/mL p-nitrophenylphosphate in 50 mM NaHCO 3 [pH 9.6] with 1 mM MgCl 2 ) and incubating at 37 C for 45-60 min. The reaction was stopped by adding 50 mL of 3N NaOH to the wells, and the absorbance was measured at 405 nm. Next, the rest of the sonicated samples was treated with 10 mL of www.moleculartherapy.org 50 mg/mL collagenase for 3 hr at 37 C, followed by Proteinase K treatment at a final concentration of 1 mg/mL at 45 C overnight. Antibiotics (P/S) were added to prevent microorganism contamination. After treatment, the samples were centrifuged at 10,000 Â g for 5 min, and 100 mL was taken out for DNA quantification using the Quanti-iT PicoGreen dsDNA Assay Kit (Invitrogen) following the manufacturer's protocol. The final ALP activity was then determined by normalizing the ALP activity to the DNA content. To measure calcium content, we added 100 mL of 1 M acetic acid to the rest of the samples, and the calcium was allowed to dissolve overnight on a shaker. The samples were diluted 1:1 in water, and the calcium content was measured with Arsenazo III method (Biolabo). HA was stained as above. For histological analyses of scaffolds, the scaffolds were fixed in 70% ethanol, embedded according to the Technovit 7100 protocol (Axlab, Vedbaek, Denmark), and cut into 25-mm sections using a KDG 95 microtome. Sections were stained with ARS by first removing the methyl methacrylate (MMA) with ethanol and rinsing in water. Sections were stained with 2% ARS solution for 1 min, then rinsed in acetone and xylene and mounted. The sections were analyzed on the Olympus IX71 Microscope.
Ectopic Bone Formation Assay
hBMSC-TERT cells were transfected as mentioned above, and 500,000 cells were seeded onto 40 mg HA/TCP (Zimmer) and incubated overnight at 5% CO 2 and 37 C. Cell-seeded HA/TCP were implanted subcutaneously into 8-week-old female NOD.CB17-Prkdcscid/J (NOD/SCID) mice as previously described. 16 Implants were then removed after 8 weeks and fixed in 4% paraformaldehyde for 24 hr followed by 3 days of decalcification in formic acid. The implants were then paraffin embedded, stained with H&E staining, and quantified as described previously. 16 Mouse experiments were approved by the Danish Animal Ethics Council.
Statistical Analyses
All results are presented as mean ± SD. Two-tailed t tests were used for comparisons in all figures except Figure 4 , where multiple group comparisons using ANOVA were performed. For the rest of the figures, only control and the experimental group were compared (thus a t test was used). Probabilities were significant when p < 0.05.
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